{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:34:47Z","timestamp":1790195687204,"version":"4.1.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s40618-017-0719-6","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T13:50:17Z","timestamp":1498657817000},"page":"1165-1174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options"],"prefix":"10.1007","volume":"40","author":[{"given":"A. A.","family":"Verhaegen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. F.","family":"Van Gaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"key":"719_CR1","unstructured":"http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\/"},{"issue":"1","key":"719_CR2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11894-015-0479-4","volume":"18","author":"V Medici","year":"2016","unstructured":"Medici V, McClave SA, Miller KR (2016) Common medications which lead to unintended alterations in weight gain or organ lipotoxicity. Curr Gastroenterol Rep 18(1):2\u201312","journal-title":"Curr Gastroenterol Rep"},{"issue":"2","key":"719_CR3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2014-3421","volume":"100","author":"JP Domecq","year":"2015","unstructured":"Domecq JP, Prutsky Gk KF, Lababidi MH et al (2015) Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 100(2):363\u2013370","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"719_CR4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.21984","volume":"55","author":"JR Curtis","year":"2006","unstructured":"Curtis JR, Westfall AO, Allison J et al (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55(3):420\u2013426","journal-title":"Arthritis Rheum"},{"issue":"5","key":"719_CR5","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/art.23561","volume":"59","author":"PK Wung","year":"2008","unstructured":"Wung PK, Anderson T, Fontaine KR et al (2008) Effects of glucocorticoids on weight change during the treatment of Wegener\u2019s granulomatosis. Wegener\u2019s Granulomatosis Etanercept Trial Research Group. Arthritis Rheum 59(5):746\u2013753","journal-title":"Arthritis Rheum"},{"issue":"3","key":"719_CR6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1399-0012.2008.00792.x","volume":"22","author":"EA Elster","year":"2008","unstructured":"Elster EA, Leeser DB, Morrissette C et al (2008) Obesity following kidney transplantation and steroid avoidance immunosuppression. Clin Transplant 22(3):354\u2013359","journal-title":"Clin Transplant"},{"key":"719_CR7","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1096\/fj.07-094144","volume":"22","author":"M Christ-Crain","year":"2008","unstructured":"Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G et al (2008) AMP-activated protein kinase mediates glucocorticoid induced metabolic changes: a novel mechanism in Cushing\u2019s syndrome. FASEB J 22:1672\u20131683","journal-title":"FASEB J"},{"issue":"1","key":"719_CR8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1421420112","volume":"112","author":"NP Bowles","year":"2015","unstructured":"Bowles NP, Karatsoreos IN, Li X et al (2015) A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. Proc Natl Acad Sci USA 112(1):285\u2013290","journal-title":"Proc Natl Acad Sci USA"},{"key":"719_CR9","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.2337\/dc12-2617","volume":"36","author":"CJ Petersons","year":"2013","unstructured":"Petersons CJ, Mangelsdorf BL, Jenkins AB et al (2013) Effects of low-dose prednisolone on hepatic and peripheral insulin sensitivity, insulin secretion, and abdominal adiposity in patients with inflammatory rheumatologic disease. Diabetes Care 36:2822\u20132829","journal-title":"Diabetes Care"},{"issue":"11","key":"719_CR10","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1210\/jc.2015-2673","volume":"100","author":"S Dube","year":"2015","unstructured":"Dube S, Slama MQ, Basu A, Rizza RA, Basu R (2015) Glucocorticoid excess increases hepatic 11\u03b2-HSD-1 activity in humans: implications in steroid-induced diabetes. J Clin Endocrinol Metab 100(11):4155\u20134162","journal-title":"J Clin Endocrinol Metab"},{"issue":"5 Pt 1","key":"719_CR11","first-page":"148","volume":"60","author":"G Wolf","year":"2002","unstructured":"Wolf G (2002) Glucocorticoids in adipocytes stimulate visceral obesity. Nutr Rev 60(5 Pt 1):148\u2013151","journal-title":"Nutr Rev"},{"issue":"6","key":"719_CR12","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s00125-014-3228-6","volume":"57","author":"A Stomby","year":"2014","unstructured":"Stomby A, Andrew R, Walker BR, Olsson T (2014) Tissue-specific dysregulation of cortisol regeneration by 11betaHSD1 in obesity: has it promised too much? Diabetologia 57(6):1100\u20131110","journal-title":"Diabetologia"},{"issue":"6","key":"719_CR13","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2337\/dc14-1630","volume":"38","author":"L Gaal Van","year":"2015","unstructured":"Van Gaal L, Scheen A (2015) Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care 38(6):1161\u20131172","journal-title":"Diabetes Care"},{"key":"719_CR14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","volume":"6","author":"D Russell-Jones","year":"2007","unstructured":"Russell-Jones D, Khan R (2007) Insulin-associated weight gain in diabetes\u2014causes, effects and coping strategies. Diabetes Obes Metab 6:799\u2013812","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"719_CR15","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1463-1326.2011.01433.x","volume":"13","author":"AE Pontiroli","year":"2011","unstructured":"Pontiroli AE, Miele L, Morabito A (2011) Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 13(11):1008\u20131019","journal-title":"Diabetes Obes Metab"},{"key":"719_CR16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s001250051172","volume":"42","author":"S M\u00e4kimattila","year":"1999","unstructured":"M\u00e4kimattila S, Nikkil\u00e4 K, Yki-Y\u00e4rvinen H (1999) Causes of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitus. Diabetologia 42:406\u2013412","journal-title":"Diabetologia"},{"issue":"3","key":"719_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1463-1326.2006.00665.x","volume":"9","author":"K Hermansen","year":"2007","unstructured":"Hermansen K, Davies M (2007) Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 9(3):209\u2013217","journal-title":"Diabetes Obes Metab"},{"key":"719_CR18","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854\u2013865","journal-title":"Lancet"},{"key":"719_CR19","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA, F.R.C.P. for the ADOPT Study Group et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427\u20132443","journal-title":"N Engl J Med"},{"key":"719_CR20","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/j.1742-1241.2006.01128.x","volume":"60","author":"J Wilding","year":"2006","unstructured":"Wilding J (2006) Thiazolidinediones, insulin resistance and obesity: finding a balance. Int J Clin Pract 60:1272\u20131280","journal-title":"Int J Clin Pract"},{"issue":"18","key":"719_CR21","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362(18):1675\u20131685","journal-title":"N Engl J Med"},{"key":"719_CR22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2337\/diab.44.11.1249","volume":"44","author":"UK Prospective Diabetes Study Group","year":"1995","unstructured":"UK Prospective Diabetes Study Group (1995) Overview of 6\u00a0years\u2019 therapy of type II diabetes: a progressive disease (UK prospective diabetes study 16). Diabetes 44:149\u2013158","journal-title":"Diabetes"},{"issue":"2","key":"719_CR23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","volume":"100","author":"CM Apovian","year":"2015","unstructured":"Apovian CM, Aronne LJ, Bessesen DH et al (2015) Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 100(2):342\u2013362","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"719_CR24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/oby.20181","volume":"21","author":"L Landsberg","year":"2013","unstructured":"Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, Sowers J (2013) Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment\u2014a position paper of The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring) 21(1):8\u201324","journal-title":"Obesity (Silver Spring)"},{"key":"719_CR25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1161\/01.HYP.37.2.250","volume":"37","author":"AM Sharma","year":"2001","unstructured":"Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC (2001) B-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37:250\u2013254","journal-title":"Hypertension"},{"issue":"7","key":"719_CR26","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.amjmed.2006.10.017","volume":"120","author":"FH Messerli","year":"2007","unstructured":"Messerli FH, Bell DS, Fonseca V, Investigators GEMINI et al (2007) Body weight changes with beta-blocker use: results of GEMINI. Am J Med 120(7):610\u2013615","journal-title":"Am J Med"},{"key":"719_CR27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJM199508103330605","volume":"333","author":"K Clement","year":"1995","unstructured":"Clement K, Vaisse C, Manning BS et al (1995) Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 333:352\u2013354","journal-title":"N Engl J Med"},{"key":"719_CR28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0026-0495(91)90053-Y","volume":"40","author":"S Welle","year":"1991","unstructured":"Welle S, Schwartz RG, Statt M (1991) Reduced metabolic rate during beta-adrenergic blockade in humans. Metabolism 40:619\u2013622","journal-title":"Metabolism"},{"issue":"3 Pt 1","key":"719_CR29","first-page":"E340","volume":"257","author":"A Astrup","year":"1989","unstructured":"Astrup A, Simonsen L, B\u00fclow J, Madsen J, Christensen NJ (1989) Epinephrine mediates facultative carbohydrate-induced thermogenesis in human skeletal muscle. Am J Physiol 257(3 Pt 1):E340\u2013E345","journal-title":"Am J Physiol"},{"issue":"suppl 7","key":"719_CR30","doi-asserted-by":"crossref","first-page":"433s","DOI":"10.1042\/cs061433s","volume":"61","author":"G Koch","year":"1981","unstructured":"Koch G, Franz IW, Lohmann FW (1981) Effects of short-term and long-term treatment with cardio-selective and non-selective beta-receptor blockade on carbohydrate and lipid metabolism and on plasma catecholamines at rest and during exercise. Clin Sci 61(suppl 7):433s\u2013435s","journal-title":"Clin Sci"},{"issue":"9557","key":"719_CR31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557):201\u2013207","journal-title":"Lancet"},{"issue":"6681","key":"719_CR32","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/bmj.298.6681.1152","volume":"298","author":"T Pollare","year":"1989","unstructured":"Pollare T, Lithell H, Selinus I, Berne C (1989) Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 298(6681):1152\u20131157","journal-title":"BMJ"},{"issue":"18","key":"719_CR33","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","volume":"292","author":"GL Bakris","year":"2004","unstructured":"Bakris GL, Fonseca V, Katholi RE, Investigators GEMINI et al (2004) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292(18):2227\u20132236","journal-title":"JAMA"},{"issue":"6","key":"719_CR34","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/1060028013519591","volume":"48","author":"TL Ripley","year":"2014","unstructured":"Ripley TL, Saseen JJ (2014) \u03b2-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother 48(6):723\u2013733","journal-title":"Ann Pharmacother"},{"issue":"2","key":"719_CR35","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamainternmed.2016.7507","volume":"177","author":"TJ Moore","year":"2017","unstructured":"Moore TJ, Mattison DR (2017) Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med 177(2):274\u2013275","journal-title":"JAMA Intern Med"},{"issue":"4","key":"719_CR36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/10673220600889256","volume":"14","author":"MT Compton","year":"2006","unstructured":"Compton MT, Daumit GL, Druss BG (2006) Cigarette smoking and overweight\/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry 14(4):212\u2013222","journal-title":"Harv Rev Psychiatry"},{"key":"719_CR37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-444-59602-4.00005-8","volume":"124","author":"M Naughton","year":"2014","unstructured":"Naughton M, Dinan TG, Scott LV (2014) Corticotropin-releasing hormone and the hypothalamic-pituitary-adrenal axis in psychiatric disease. Handb Clin Neurol 124:69\u201391","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"719_CR38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/npp.2016.90","volume":"42","author":"C M\u00e9nard","year":"2017","unstructured":"M\u00e9nard C, Pfau ML, Hodes GE, Russo SJ (2017) Immune and neuroendocrine mechanisms of stress vulnerability and resilience. Neuropsychopharmacology 42(1):62\u201380","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"719_CR39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/npp.2016.123","volume":"42","author":"L Capuron","year":"2017","unstructured":"Capuron L, Lasselin J, Castanon N (2017) Role of adiposity-driven inflammation in depressive morbidity. Neuropsychopharmacology 42(1):115\u2013128","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"719_CR40","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.biopsych.2009.12.003","volume":"67","author":"JC Chuang","year":"2010","unstructured":"Chuang JC, Krishnan V, Yu HG et al (2010) A beta3-adrenergic-leptin-melanocortin circuit regulates behavioral and metabolic changes induced by chronic stress. Biol Psychiatry 67(11):1075\u20131082","journal-title":"Biol Psychiatry"},{"issue":"3","key":"719_CR41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-3956(03)00018-9","volume":"37","author":"U Zimmermann","year":"2003","unstructured":"Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollm\u00e4cher T (2003) Epidemiology, implications and mechanisms underlying drug induced weight gain in psychiatric patients. J Psychiatr Res 37(3):193\u2013220","journal-title":"J Psychiatr Res"},{"issue":"11","key":"719_CR42","doi-asserted-by":"crossref","first-page":"e1417","DOI":"10.4088\/JCP.14m09358","volume":"76","author":"F Vandenberghe","year":"2015","unstructured":"Vandenberghe F, Gholam-Rezaee M, Saig\u00ed-Morgui N et al (2015) Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry 76(11):e1417\u2013e1423","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"719_CR43","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"27","author":"American Diabetes Association, American Psychiatric Association","year":"2004","unstructured":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists et al (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2):596\u2013601","journal-title":"Diabetes Care"},{"key":"719_CR44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1749-6632.1987.tb36212.x","volume":"499","author":"JG Bernstein","year":"1987","unstructured":"Bernstein JG (1987) Induction of obesity by psychotropic drugs. Ann N Y Acad Sci 499:203\u2013215","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"719_CR45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.schres.2009.07.011","volume":"115","author":"GC Smith","year":"2009","unstructured":"Smith GC, Vickers MH, Cognard E, Shepherd PR (2009) Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr Res 115(1):30\u201340","journal-title":"Schizophr Res"},{"key":"719_CR46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.2009.05266.x","volume":"1190","author":"KL Stanhope","year":"2010","unstructured":"Stanhope KL, Havel PJ (2010) Fructose consumption: recent results and their potential implications. Ann N Y Acad Sci 1190:15\u201324","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"719_CR47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2174\/1871530315666150623092031","volume":"15","author":"H Himmerich","year":"2015","unstructured":"Himmerich H, Minkwitz J, Kirkby KC (2015) Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Disord Drug Targets 15(4):252\u2013260","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"suppl 7","key":"719_CR48","first-page":"4","volume":"62","author":"DE Casey","year":"2001","unstructured":"Casey DE, Zorn SH (2001) The pharmacology of weight gain with antipsychotics. Clin Psych 62(suppl 7):4\u201310","journal-title":"Clin Psych"},{"issue":"11","key":"719_CR49","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ebiom.2015.10.018","volume":"2","author":"SM Bahra","year":"2015","unstructured":"Bahra SM, Weidemann BJ, Castro AN et al (2015) Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine 2(11):1725\u20131734","journal-title":"EBioMedicine"},{"issue":"9","key":"719_CR50","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3858\/emm.2012.44.9.062","volume":"44","author":"JE Oh","year":"2012","unstructured":"Oh JE, Cho YM, Kwak SN et al (2012) Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics. Exp Mol Med 44(9):545\u2013553","journal-title":"Exp Mol Med"},{"issue":"5","key":"719_CR51","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/tpj.2009.67","volume":"10","author":"C Pavan","year":"2010","unstructured":"Pavan C, Vindigni V, Michelotto L et al (2010) Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-\u03b2. Pharmacogenomics J 10(5):408\u2013417","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"719_CR52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bpg.2013.03.007","volume":"27","author":"A Everard","year":"2013","unstructured":"Everard A, Cani PD (2013) Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 27(1):73\u201383","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"3","key":"719_CR53","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/phar.1890","volume":"37","author":"SA Flowers","year":"2017","unstructured":"Flowers SA, Evans SJ, Ward KM, McInnis MG, Ellingrod VL (2017) Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort. Pharmacotherapy 37(3):261\u2013267","journal-title":"Pharmacotherapy"},{"issue":"10","key":"719_CR54","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11920-014-0473-9","volume":"16","author":"TA Shams","year":"2014","unstructured":"Shams TA, M\u00fcller DJ (2014) Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed. Curr Psychiatry Rep 16(10):473","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"719_CR55","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/mp.2011.109","volume":"17","author":"TA Lett","year":"2012","unstructured":"Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, M\u00fcller DJ (2012) Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 17(3):242\u2013266","journal-title":"Mol Psychiatry"},{"issue":"10","key":"719_CR56","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4088\/JCP.09r05346blu","volume":"71","author":"A Serreti","year":"2010","unstructured":"Serreti A, Mandelli L (2010) Antidepresants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 71(10):1259\u20131272","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"719_CR57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/10401230209147454","volume":"14","author":"PS Massand","year":"2002","unstructured":"Massand PS, Gupta S (2002) Long term side effects of newer generation antidepressants SSRIS, venlafaxine, nefazodone, bupropion and mirtazapine. Ann Clin Psychiatry 14(3):175\u2013182","journal-title":"Ann Clin Psychiatry"},{"issue":"1","key":"719_CR58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/14737175.7.1.17","volume":"7","author":"KM Gadde","year":"2007","unstructured":"Gadde KM, Xiong GL (2007) Bupropion for weight reduction. Expert Rev Neurother 7(1):17\u201324","journal-title":"Expert Rev Neurother"},{"key":"719_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2014.04.004","volume":"84","author":"SK Billes","year":"2014","unstructured":"Billes SK, Sinnayah P, Cowley MA (2014) Naltrexone\/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res 84:1\u201311","journal-title":"Pharmacol Res"},{"issue":"3","key":"719_CR60","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/0269881105057515","volume":"20","author":"C Livingstone","year":"2006","unstructured":"Livingstone C, Rampes H (2006) Lithium: a review of its metabolic adverse effects. J Psychopharmacol 20(3):347\u2013355","journal-title":"J Psychopharmacol"},{"issue":"3","key":"719_CR61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00004850-199007000-00007","volume":"5","author":"Y Chen","year":"1990","unstructured":"Chen Y, Silverstone T (1990) Lithium and weight gain. Int Clin Psychopharmacol 5(3):217\u2013225","journal-title":"Int Clin Psychopharmacol"},{"issue":"23","key":"719_CR62","doi-asserted-by":"crossref","first-page":"e3784","DOI":"10.1097\/MD.0000000000003784","volume":"95","author":"M Sohn","year":"2016","unstructured":"Sohn M, Moga DC, Blumenschein K, Talbert J (2016) National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore) 95(23):e3784","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"719_CR63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2009.01425.x","volume":"121","author":"H Verdoux","year":"2010","unstructured":"Verdoux H, Tournier M, B\u00e9gaud B (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 121(1):4\u201310","journal-title":"Acta Psychiatr Scand"},{"issue":"11","key":"719_CR64","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156(11):1686\u20131696","journal-title":"Am J Psychiatry"},{"issue":"Suppl 7","key":"719_CR65","first-page":"22","volume":"62","author":"DB Allison","year":"2001","unstructured":"Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62(Suppl 7):22\u201331","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"719_CR66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/PCC.v10n0104","volume":"10","author":"G Balf","year":"2008","unstructured":"Balf G, Stewart DT, Whitehead R, Baker RA (2008) Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. Prim Care Companion J Clin Psychiatry 10(1):15\u201324","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"10","key":"719_CR67","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/14740338.2016.1201475","volume":"15","author":"L Orsolini","year":"2016","unstructured":"Orsolini L, Tomasetti C, Valchera A et al (2016) An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf 15(10):1329\u20131347","journal-title":"Expert Opin Drug Saf"},{"issue":"16","key":"719_CR68","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","volume":"302","author":"CU Correll","year":"2009","unstructured":"Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302(16):1765\u20131773","journal-title":"JAMA"},{"issue":"6","key":"719_CR69","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/JCP.0b013e3181faf670","volume":"30","author":"VP Hoffmann","year":"2010","unstructured":"Hoffmann VP, Case M, Stauffer VL, Jacobson JG, Conley RR (2010) Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled trials. J Clin Psychopharmacol 30(6):656\u2013660","journal-title":"J Clin Psychopharmacol"},{"key":"719_CR70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-244X-5-3","volume":"5","author":"H Ascher-Svanum","year":"2005","unstructured":"Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ (2005) Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 5:3","journal-title":"BMC Psychiatry"},{"issue":"2","key":"719_CR71","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","volume":"39","author":"AJ Mitchell","year":"2013","unstructured":"Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis. Schizophr Bull 39(2):306\u2013318","journal-title":"Schizophr Bull"},{"issue":"2","key":"719_CR72","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1463-1326.2005.00495.x","volume":"8","author":"RI Holt","year":"2006","unstructured":"Holt RI, Peveler RC (2006) Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 8(2):125\u2013135","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"719_CR73","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M Hert De","year":"2011","unstructured":"De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8(2):114\u2013126","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"719_CR74","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tem.2014.07.004","volume":"25","author":"JS Ballon","year":"2014","unstructured":"Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA (2014) Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab 25(11):593\u2013600","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"719_CR75","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0091-3057(03)00079-0","volume":"75","author":"DS Dwyer","year":"2003","unstructured":"Dwyer DS, Donohoe D (2003) Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 75(2):255\u2013260","journal-title":"Pharmacol Biochem Behav"},{"issue":"1\u20133","key":"719_CR76","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.schres.2008.07.006","volume":"105","author":"GL Daumit","year":"2008","unstructured":"Daumit GL, Goff DC, Meyer JM et al (2008) Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 105(1\u20133):175\u2013187","journal-title":"Schizophr Res"},{"issue":"Suppl 9","key":"719_CR77","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1528-1167.2007.01402.x","volume":"48","author":"E Ben-Menachem","year":"2007","unstructured":"Ben-Menachem E (2007) Weight issues for people with epilepsy\u2014a review. Epilepsia 48(Suppl 9):42\u201345","journal-title":"Epilepsia"},{"issue":"5","key":"719_CR78","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1111\/j.1467-789X.2010.00800.x","volume":"12","author":"A Verrotti","year":"2011","unstructured":"Verrotti A, D\u2019Egidio C, Mohn A, Coppola G, Chiarelli F (2011) Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev 12(5):e32\u2013e43","journal-title":"Obes Rev"},{"issue":"1\u20132","key":"719_CR79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2013.08.016","volume":"107","author":"V Belcastro","year":"2013","unstructured":"Belcastro V, D\u2019Egidio C, Striano P, Verrotti A (2013) Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res 107(1\u20132):1\u20138","journal-title":"Epilepsy Res"},{"issue":"4","key":"719_CR80","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/jcb.20555","volume":"96","author":"HY Wong","year":"2005","unstructured":"Wong HY, Chu TS, Lai JC et al (2005) Sodium valproate inhibits glucose transport and exacerbates Glut1-deficiency in vitro. J Cell Biochem 96(4):775\u2013785","journal-title":"J Cell Biochem"},{"issue":"9","key":"719_CR81","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.4254\/wjh.v7.i9.1251","volume":"7","author":"E Farinelli","year":"2015","unstructured":"Farinelli E, Giampaoli D, Cenciarini A, Cercado E, Verrotti A (2015) Valproic acid and nonalcoholic fatty liver disease: a possible association? World J Hepatol 7(9):1251\u20131257","journal-title":"World J Hepatol"},{"issue":"suppl 14","key":"719_CR82","first-page":"16","volume":"62","author":"AC Swann","year":"2001","unstructured":"Swann AC (2001) Major system toxicities and side effects of anticonvulsants. J Clin Psychiatry 62(suppl 14):16\u201321","journal-title":"J Clin Psychiatry"},{"key":"719_CR83","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/978-3-642-24716-3_20","volume":"209","author":"J Antel","year":"2012","unstructured":"Antel J, Hebebrand J (2012) Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol 209:433\u2013466","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"719_CR84","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1345\/aph.1R501","volume":"47","author":"SM Smith","year":"2013","unstructured":"Smith SM, Meyer M, Trinkley KE (2013) Phentermine\/topiramate for the treatment of obesity. Ann Pharmacother 47(3):340\u2013349","journal-title":"Ann Pharmacother"},{"key":"719_CR85","doi-asserted-by":"crossref","unstructured":"Gierisch JM, Nieuwsma JA, Bradford DW et al (2013) Interventions to improve cardiovascular risk factors in people with serious mental illness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US). Report No.: 13-EHC063-EF. AHRQ Comparative Effectiveness Reviews","DOI":"10.1037\/e553762013-001"},{"issue":"10","key":"719_CR86","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/oby.21205","volume":"23","author":"CA Green","year":"2015","unstructured":"Green CA, Yarborough BJ, Leo MC et al (2015) The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Obesity (Silver Spring) 23(10):1995\u20132001","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"719_CR87","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1192\/bjp.bp.107.042853","volume":"193","author":"M Alvarez-Jim\u00e9nez","year":"2008","unstructured":"Alvarez-Jim\u00e9nez M, Hetrick SE, Gonz\u00e1lez-Blanch C, Gleeson JF, McGorry PD (2008) Non pharmacological management of antipsychotic-induced weight gain: systematic review and meta analysis of randomised controlled trials. Br J Psychiatry 193(2):101\u2013107","journal-title":"Br J Psychiatry"},{"issue":"11","key":"719_CR88","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4088\/JCP.12028ah1","volume":"74","author":"JW Newcomer","year":"2013","unstructured":"Newcomer JW, Weiden PJ, Buchanan RW (2013) Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry 74(11):1108\u20131120","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"719_CR89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3810\/pgm.2013.09.2706","volume":"125","author":"M Hasnain","year":"2013","unstructured":"Hasnain M, Vieweg WV (2013) Weight considerations in psychotropic drug prescribing and switching. Postgrad Med 125(5):117\u2013129","journal-title":"Postgrad Med"},{"key":"719_CR90","doi-asserted-by":"publisher","unstructured":"Mukundan A, Faulkner G, Cohn T, Remington G (2010) Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev (12):CD006629. doi: 10.1002\/14651858.CD006629.pub2","DOI":"10.1002\/14651858.CD006629.pub2"},{"issue":"6","key":"719_CR91","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","volume":"40","author":"Y Mizuno","year":"2014","unstructured":"Mizuno Y, Suzuki T, Nakagawa A et al (2014) Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 40(6):1385\u20131403","journal-title":"Schizophr Bull"},{"issue":"5","key":"719_CR92","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/JCP.0000000000000392","volume":"35","author":"W Zheng","year":"2015","unstructured":"Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J (2015) Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 35(5):499\u2013509","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"719_CR93","doi-asserted-by":"crossref","first-page":"e93310","DOI":"10.1371\/journal.pone.0093310","volume":"9","author":"Y Hu","year":"2014","unstructured":"Hu Y, Young AJ, Ehli EA et al (2014) Metformin and berberine prevent olanzapine-induced weight gain in rats. PLoS One 9(3):e93310","journal-title":"PLoS One"},{"key":"719_CR94","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1741-7015-10-92","volume":"10","author":"BH Ebdrup","year":"2012","unstructured":"Ebdrup BH, Knop FK, Ish\u00f8y PL et al (2012) Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med 10:92","journal-title":"BMC Med"},{"issue":"1\u20133","key":"719_CR95","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","volume":"103","author":"K Lykkegaard","year":"2008","unstructured":"Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB (2008) The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res 103(1\u20133):94\u2013103","journal-title":"Schizophr Res"},{"issue":"2","key":"719_CR96","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11011-014-9591-7","volume":"30","author":"AN Sharma","year":"2015","unstructured":"Sharma AN, Ligade SS, Sharma JN, Shukla P, Elased KM, Lucot JB (2015) GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab Brain Dis 30(2):519\u2013527","journal-title":"Metab Brain Dis"},{"key":"719_CR97","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220","author":"JR Larsen","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MSL et al (2017) Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. doi: 10.1001\/jamapsychiatry.2017.1220","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"719_CR98","first-page":"31","volume":"11","author":"N M\u00fcller","year":"2010","unstructured":"M\u00fcller N (2010) COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 11(1):31\u201342","journal-title":"Curr Opin Investig Drugs"},{"issue":"12","key":"719_CR99","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/oby.2010.51","volume":"18","author":"C Gross","year":"2010","unstructured":"Gross C, Blasey CM, Roe RL, Belanoff JK (2010) Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring.) 18(12):2295\u20132300","journal-title":"Obesity (Silver Spring.)"},{"issue":"6","key":"719_CR100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1463-1326.2009.01185.x","volume":"12","author":"JK Belanoff","year":"2010","unstructured":"Belanoff JK, Blasey CM, Clark RD, Roe RL (2010) Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain. Diabetes Obes Metab 12(6):545\u2013547","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"719_CR101","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/npp.2017.20","volume":"42","author":"A Rimessi","year":"2017","unstructured":"Rimessi A, Pavan C, Ioannidi E et al (2017) Protein kinase C \u03b2: a new target therapy to prevent the long-term atypical antipsychotic-induced weight gain. Neuropsychopharmacology 42(7):1491\u20131501","journal-title":"Neuropsychopharmacology"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-017-0719-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0719-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0719-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T03:23:57Z","timestamp":1659151437000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-017-0719-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":101,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1007\/s40618-017-0719-6","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]}}}